NASDAQ:DRNADicerna Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dicerna Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $19.56 -0.95 (-4.63 %) (As of 06/4/2020 04:00 PM ET) Add Compare Share Today's Range$19.11Now: $19.56▼$20.7050-Day Range$19.70MA: $21.59▼$24.3552-Week Range$11.75Now: $19.56▼$27.68Volume836,319 shsAverage Volume655,496 shsMarket Capitalization$1.45 billionP/E RatioN/ADividend YieldN/ABeta1.84 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases. Its principal development programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and a program for an undisclosed rare liver disease. The company's development programs also comprise additional rare disease programs; a program for the treatment of hypercholesterolemia; and various programs in various therapeutic areas involving liver function. The company has strategic collaborations with Eli Lilly and Company, Alexion Pharmaceuticals, Inc., and Boehringer Ingelheim International GmbH. Dicerna Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Cambridge, Massachusetts.Read More Beat the Market (BTM) Rank™ 4.5 Analyst's Opinion Consensus RatingDicerna Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 11 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.20, Dicerna Pharmaceuticals has a potential upside of 74.8% from its current price of $19.56.Amount of Analyst CoverageDicerna Pharmaceuticals has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Community Rank Outperform VotesDicerna Pharmaceuticals has received 425 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDicerna Pharmaceuticals has received 279 “underperform” votes. (Add your “underperform” vote.)Community SentimentDicerna Pharmaceuticals has received 60.37% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Dicerna Pharmaceuticals and other stocks. Vote “Outperform” if you believe DRNA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DRNA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDicerna Pharmaceuticals does not currently pay a dividend.Dividend GrowthDicerna Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dicerna Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,405,810.00 in company stock.Percentage Held by InsidersOnly 21.28% of the stock of Dicerna Pharmaceuticals is held by insiders.Percentage Held by Institutions82.78% of the stock of Dicerna Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Dicerna Pharmaceuticals are expected to decrease in the coming year, from $0.40 to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dicerna Pharmaceuticals is -11.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dicerna Pharmaceuticals is -11.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDicerna Pharmaceuticals has a P/B Ratio of 8.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 4.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.70 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRNA Previous Symbol CUSIPN/A CIK1399529 Webwww.dicerna.com Phone617-621-8097Debt Debt-to-Equity Ratio0.12 Current Ratio2.90 Quick Ratio2.90Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio48.90 P/E GrowthN/A Sales & Book Value Annual Sales$23.90 million Price / Sales60.50 Cash FlowN/A Price / Cash FlowN/A Book Value$2.22 per share Price / Book8.81Profitability EPS (Most Recent Fiscal Year)($1.76) Net Income$-120,460,000.00 Net Margins-213.04% Return on Equity-74.79% Return on Assets-22.53%Miscellaneous Employees78 Outstanding Shares73,920,000Market Cap$1.45 billion Next Earnings Date8/13/2020 (Estimated) OptionableOptionable NASDAQ:DRNA Rates by TradingView Receive DRNA News and Ratings via Email Sign-up to receive the latest news and ratings for DRNA and its competitors with MarketBeat's FREE daily newsletter. Dicerna Pharmaceuticals (NASDAQ:DRNA) Frequently Asked Questions How has Dicerna Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, DRNA stock has increased by 15.9% and is now trading at $19.56. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Dicerna Pharmaceuticals? 11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last year. There are currently 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Dicerna Pharmaceuticals. When is Dicerna Pharmaceuticals' next earnings date? Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 13th 2020. View our earnings forecast for Dicerna Pharmaceuticals. How were Dicerna Pharmaceuticals' earnings last quarter? Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) released its earnings results on Thursday, May, 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the Zacks' consensus estimate of $0.28 by $0.59. The biopharmaceutical company earned $34.03 million during the quarter, compared to analysts' expectations of $59.61 million. Dicerna Pharmaceuticals had a negative net margin of 213.04% and a negative return on equity of 74.79%. View Dicerna Pharmaceuticals' earnings history. What price target have analysts set for DRNA? 11 equities research analysts have issued 1 year price objectives for Dicerna Pharmaceuticals' shares. Their forecasts range from $25.00 to $50.00. On average, they expect Dicerna Pharmaceuticals' stock price to reach $34.20 in the next year. This suggests a possible upside of 74.8% from the stock's current price. View analysts' price targets for Dicerna Pharmaceuticals. Has Dicerna Pharmaceuticals been receiving favorable news coverage? News articles about DRNA stock have trended negative this week, according to InfoTrie. The research firm ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dicerna Pharmaceuticals earned a news impact score of -2.7 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutDicerna Pharmaceuticals. Are investors shorting Dicerna Pharmaceuticals? Dicerna Pharmaceuticals saw a decline in short interest in May. As of May 15th, there was short interest totaling 3,040,000 shares, a decline of 15.6% from the April 30th total of 3,600,000 shares. Based on an average daily volume of 675,700 shares, the short-interest ratio is currently 4.5 days. Currently, 4.9% of the shares of the stock are sold short. View Dicerna Pharmaceuticals' Current Options Chain. Who are some of Dicerna Pharmaceuticals' key competitors? Some companies that are related to Dicerna Pharmaceuticals include United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Emergent Biosolutions (EBS), Zai Lab (ZLAB), PPD (SDGR), Ultragenyx Pharmaceutical (RARE), Mirati Therapeutics (MRTX), Evotec (EVTCY), Global Blood Therapeutics (GBT), Nektar Therapeutics (NKTR), Blueprint Medicines (BPMC), GW Pharmaceuticals PLC- (GWPH) and Biohaven Pharmaceutical (BHVN). View all competitors. What other stocks do shareholders of Dicerna Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Amarin (AMRN), Strongbridge Biopharma (SBBP), Arbutus Biopharma (ABUS), TG Therapeutics (TGTX), Crispr Therapeutics (CRSP), Gilead Sciences (GILD), Exelixis (EXEL), ImmunoGen (IMGN) and Array Biopharma (ARRY). Who are Dicerna Pharmaceuticals' key executives? Dicerna Pharmaceuticals' management team includes the following people: Dr. Douglas M. Fambrough III, Co-Founder, CEO, Pres & Director (Age 50)Dr. Bob D. Brown, Chief Scientific Officer & Sr. VP (Age 54)Dr. Ralf H. Rosskamp, Chief Medical Officer (Age 66)Dr. Mark Behlke, Co-Founder & Member of Scientific Advisory BoardProf. John J. Rossi, Co-Founder & Chairman of Scientific Advisory Board (Age 72) What is Dicerna Pharmaceuticals' stock symbol? Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA." Who are Dicerna Pharmaceuticals' major shareholders? Dicerna Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (6.85%), Wellington Management Group LLP (5.24%), UBS Group AG (2.92%), Eagle Asset Management Inc. (2.36%), State Street Corp (2.28%) and Driehaus Capital Management LLC (1.37%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Brian K Halak, Dennis Langer, Douglas Fambrough, James B Weissman, John B Green and Peter Kolchinsky. View institutional ownership trends for Dicerna Pharmaceuticals. Which major investors are selling Dicerna Pharmaceuticals stock? DRNA stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, Federated Hermes Inc., Emerald Mutual Fund Advisers Trust, Morgan Stanley, JPMorgan Chase & Co., EAM Investors LLC, Squarepoint Ops LLC, and WINTON GROUP Ltd. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, and Peter Kolchinsky. View insider buying and selling activity for Dicerna Pharmaceuticals. Which major investors are buying Dicerna Pharmaceuticals stock? DRNA stock was bought by a variety of institutional investors in the last quarter, including Wellington Management Group LLP, BlackRock Inc., Invesco Ltd., AXA, Assenagon Asset Management S.A., Two Sigma Advisers LP, Schroder Investment Management Group, and Connor Clark & Lunn Investment Management Ltd.. View insider buying and selling activity for Dicerna Pharmaceuticals. How do I buy shares of Dicerna Pharmaceuticals? Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Dicerna Pharmaceuticals' stock price today? One share of DRNA stock can currently be purchased for approximately $19.56. How big of a company is Dicerna Pharmaceuticals? Dicerna Pharmaceuticals has a market capitalization of $1.45 billion and generates $23.90 million in revenue each year. The biopharmaceutical company earns $-120,460,000.00 in net income (profit) each year or ($1.76) on an earnings per share basis. Dicerna Pharmaceuticals employs 78 workers across the globe. What is Dicerna Pharmaceuticals' official website? The official website for Dicerna Pharmaceuticals is www.dicerna.com. How can I contact Dicerna Pharmaceuticals? Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected] This page was last updated on 6/5/2020 by MarketBeat.com Staff
